A new trading day began on Monday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price down -6.28% from the previous day of trading, before settling in for the closing price of $13.69. ARQT’s price has ranged from $6.99 to $16.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 349.37% over the past five years. Meanwhile, its annual earnings per share averaged 50.49%. With a float of $104.43 million, this company’s outstanding shares have now reached $117.85 million.
Let’s look at the performance matrix of the company that is accounted for 342 employees. In terms of profitability, gross margin is 90.27%, operating margin of -65.33%, and the pretax margin is -70.92%.
Arcutis Biotherapeutics Inc (ARQT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 11.97%, while institutional ownership is 101.77%. The most recent insider transaction that took place on Mar 03 ’25, was worth 272,089. Before that another transaction happened on Mar 03 ’25, when Company’s Officer proposed sale 3,263 for $13.03, making the entire transaction worth $42,520.
Arcutis Biotherapeutics Inc (ARQT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 50.49% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach 0.26 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 2.83 million, a positive change from its year-to-date volume of 2.22 million. As of the previous 9 days, the stock’s Stochastic %D was 61.95%. Additionally, its Average True Range was 1.05.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 58.75%, which indicates a significant decrease from 60.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.14% in the past 14 days, which was higher than the 71.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.54, while its 200-day Moving Average is $10.71. Nevertheless, the first resistance level for the watch stands at $13.56 in the near term. At $14.30, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.74. If the price goes on to break the first support level at $12.38, it is likely to go to the next support level at $11.94. Assuming the price breaks the second support level, the third support level stands at $11.20.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.52 billion, the company has a total of 118,638K Shares Outstanding. Currently, annual sales are 59,610 K while annual income is -262,140 K. The company’s previous quarter sales were 44,760 K while its latest quarter income was -41,540 K.
